Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks
Phase of Trial: Phase III
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Metyrapone (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- Acronyms PROMPT
- Sponsors HRA Pharma
- 10 Jun 2017 Biomarkers information updated
- 14 Feb 2017 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018.
- 14 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2018.